Just when you thought Mylan's (MYL) EpiPen controversy had subsided, it resurfaces. The company's half-price version of its life-saving allergy treatment will be available by the end of this year, potentially months later than a timeline Mylan gave in August, according to Bloomberg. The cheaper version of the EpiPen shot will cost $300. Mylan spokeswoman Nina Devlin told Bloomberg that Mylan expected the so-called authorized generic EpiPen this year, "once we have assured that sufficient inventory will be available to meet anticipated orders."
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.